--- title: "週二 Replimune 的股票發生了什麼情況？" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/285246812.md" description: "Replimune Inc.（納斯達克代碼：REPL）面臨顯著的股價下跌，跌幅為 15.18%，至 2.58 美元，此次下跌與 FDA 領導層受到的批評有關，批評者為專員 Marty Makary。FDA 拒絕 Replimune 的黑色素瘤治療方案引發了對審查流程不一致和患者獲得潛在救命療法機會有限的擔憂。Makary 為 FDA 的決定辯護，表示多個獨立審查團隊支持這些拒絕決定。過去一個月，Replimune 的股價下跌了約 63.5%，而標準普爾 500 指數則上漲了 10.3%" datetime: "2026-05-05T17:44:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285246812.md) - [en](https://longbridge.com/en/news/285246812.md) - [zh-HK](https://longbridge.com/zh-HK/news/285246812.md) --- # 週二 Replimune 的股票發生了什麼情況？ U.S. Food and Drug Administration (FDA) Commissioner **Marty Makary** defended his leadership in a CNBC interview aired Tuesday, growing criticism with concerns centering on drug approval decisions and internal leadership disputes that have sparked political and public backlash. Among the companies affected by the FDA decisions is **Replimune Inc.**. **• Replimune Group ( REPL ) stock is showing notable weakness. Why is REPL stock dropping?** ## **Makary Responds To Mounting Criticism Over FDA Leadership** A Bloomberg report published Monday characterized Makary's tenure at the FDA as marked by internal disruption, leadership instability, and increasing frustration across the pharmaceutical industry. Reports of staff conflicts, frequent leadership turnover, and an inconsistent drug review process have unsettled biotech companies and drawn attention from lawmakers. While no immediate removal is planned, insiders say another major misstep could jeopardize his position, despite his efforts to implement reforms and defend his record. The Wall Street Journal report highlighted that a series of FDA rejections involving rare-disease and cancer treatments has drawn sharp reactions. Critics argue the agency has reversed prior guidance and relied on technical grounds to deny access to potentially life-saving therapies. **Read Also: Controversial FDA Vaccines Chief Vinay Prasad To Leave Agency In April** ## **Replimune Case Fuels Debate Over FDA Review Practices** One such case involves a melanoma treatment by **Replimune Inc.**, where roughly one-third of patients unresponsive to other immunotherapies reportedly achieved remission. After FDA rejection in April, Replimune ( REPL ) highlighted what it described as inconsistencies in the FDA’s review process. According to the company, a new review team was assigned during the resubmission phase, replacing the original team that had engaged with the company earlier. Critics contend the FDA's decision limits patient access despite promising outcomes. Similarly, a gene therapy developed by **uniQure N.V.** for Huntington's disease showed a 75% slowing in disease progression during trials. The FDA has called for an additional study involving a control group undergoing sham brain surgery, a requirement some experts have labeled unethical. ## **Makary Defends FDA Scientists and Decision Integrity** "I think that article in The Wall Street Journal is the ninth article they've posted in that opinion section, begging for Replimune's ( REPL ) approval," Makary said in the CNBC interview. "I don't work for Replimune ( REPL ), I work for the American people, and I stand by the scientists at the FDA." Makary told CNBC that three independent review teams reached the same conclusion and rejected claims that the FDA engaged in "corrupt sweetheart deals." Replimune ( REPL ) has alleged unfair treatment by the agency. He added that he supports the FDA's scientific review teams, arguing that commissioner-level overrides have historically led to poor outcomes. He pointed to past decisions, including the approval of **Biogen Inc.’s** Alzheimer's drug Aduhelm and authorization of a COVID-19 booster for low-risk children, as examples. **REPL Price Action:** Replimune Group ( REPL ) shares were down 15.18% at $2.58 at the time of publication on Tuesday, according to Benzinga Pro. Over the past month, REPL has declined about 63.5% versus a 10.3% rise in the S&P 500 and is down roughly 69% year-to-date compared to the index’s 5.5% gain. **Read Also: How Corporate Bitcoin Adoption Has Created New BTC Investment Vehicles** _Image via Shutterstock_ ### 相關股票 - [REPL.US](https://longbridge.com/zh-HK/quote/REPL.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [LABD.US](https://longbridge.com/zh-HK/quote/LABD.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [QURE.US](https://longbridge.com/zh-HK/quote/QURE.US.md) - [BIIB.US](https://longbridge.com/zh-HK/quote/BIIB.US.md) - [.SPX.US](https://longbridge.com/zh-HK/quote/.SPX.US.md) ## 相關資訊與研究 - [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md) - [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md) - [儲局會議記錄顯示 大多數官員警告通脹率若持續高於 2% 需考慮加息](https://longbridge.com/zh-HK/news/287171073.md) - [Co-Diagnostics 通過新的 Bundibugyo 病毒檢測策略加強埃博拉病毒的防範準備；股價上漲](https://longbridge.com/zh-HK/news/286956797.md) - [Immix Biopharma 宣佈在復發/難治性 AL 澱粉樣變性臨牀試驗 NEXICART-2 的中期更新中完全緩解率達 95%](https://longbridge.com/zh-HK/news/287200923.md)